|
Eckert & Ziegler SE / Key word(s): Quarter Results/Preliminary Results Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed. 22-Apr-2024 / 14:49 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. 1st Quarter 2024:
Forecast FY 2024:
Berlin, 22 April 2024. According to preliminary calculations, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) achieved sales of EUR 67.6 million in the first quarter of 2024 (previous year: EUR 57.9 million). The key figure EBIT before special items introduced as part of the 2024 forecast amounted to EUR 15.0 million in the first quarter of 2024 (previous year: EUR 10.7 million). Net income, which is only reported here on a comparative basis, increased to EUR 8.5 million (previous year: EUR 4.7 million). The forecast for the 2024 financial year published on March 22, 2024 remains unchanged. The Executive Board continues to expect sales of just under EUR 265 million and EBIT before special items of around EUR 50 million. The complete figures for the first quarter of 2024 will be published on May 14, 2024. Contact: End of Inside Information 22-Apr-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Watch: Why fentanyl withdrawal is agony and how medication can prevent it
Over 2 million Americans have opioid use disorder, according to some estimates. Illicit opioids such as heroin and fentanyl were responsible for over 80,000 U.S.
March 5, 2024